TY - JOUR
T1 - Safety Evaluation of Fine Bubble Shower Washing for Patients With Atopic Dermatitis
T2 - A Double-Blind, Randomized, Prospective Crossover Clinical Trial
AU - Kato, Hiroshi
AU - Tamagawa-Mineoka, Risa
AU - Nakatani, Eiji
AU - Yoshimura, Kenichi
AU - Yasui, Yukiko
AU - Kato, Kasumi
AU - Nakamura, Motoki
AU - Kurachi, Ako
AU - Takeda, Soshi
AU - Morita, Akimichi
N1 - Publisher Copyright:
© 2025 The Author(s). The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
PY - 2026/3
Y1 - 2026/3
N2 - Atopic dermatitis (AD) involves chronic eczema resulting from barrier dysfunction. Fine bubble (FB) technology generates microbubbles (< 100 μm) and ultrafine bubbles (< 1 μm) for surfactant-sparing cleansing. We assessed the short-term safety of an FB shower in AD. In this double-blind, randomized, crossover study, adults with mild AD completed two 2-week periods separated by a 2-week washout in sequence. Bathing instructions and petrolatum moisturizer use were standardized and enforced. The Eczema Area and Severity Index (EASI) was scored using whole-body photographs by a blinded team. Transepidermal water loss (TEWL) and stratum corneum hydration were measured on Days 0, 14, and 28. Because baselines were unavailable for the second 2-week period, the primary analysis compared Day 0–14 changes between groups using baseline-adjusted analysis of covariance; Day 0–28 changes were also explored. The primary outcomes were EASI changes; TEWL and hydration were the secondary outcomes. Groups used a conventional shower (control) first and then FB shower second or vice versa (once each). Twenty-three participants were analyzed (mean age 40.9 ± 8 years; 83% male). Day 0–14 EASI changes did not differ between FB and control (0.62 ± 2.21 vs. 0.05 ± 0.68; F = 0.93, p = 0.35). EASI changes to Day 28 were nonsignificant (0.02 ± 1.65 vs. −0.03 ± 1.02; p = 0.90). TEWL changes for Days 0–14 (0.31 ± 4.75 vs. 1.09 ± 6.21 g/m2/h) and to Day 28 (5.49 ± 14.43 vs. −0.27 ± 5.28 g/m2/h) showed no between-group differences. Hydration changes were similar for Days 0–14 (5.53 ± 13.23 vs. 6.14 ± 7.96 AU) and to Day 28 (18.41 ± 10.33 vs. 21.09 ± 11.07 AU). No serious adverse events or discontinuations for worsening symptoms occurred. Under standardized, low-irritant conditions, the FB shower was well-tolerated by adults with mild AD and did not worsen severity or barrier indices over 4 weeks. However, the superiority of FB to a conventional shower was not demonstrated.
AB - Atopic dermatitis (AD) involves chronic eczema resulting from barrier dysfunction. Fine bubble (FB) technology generates microbubbles (< 100 μm) and ultrafine bubbles (< 1 μm) for surfactant-sparing cleansing. We assessed the short-term safety of an FB shower in AD. In this double-blind, randomized, crossover study, adults with mild AD completed two 2-week periods separated by a 2-week washout in sequence. Bathing instructions and petrolatum moisturizer use were standardized and enforced. The Eczema Area and Severity Index (EASI) was scored using whole-body photographs by a blinded team. Transepidermal water loss (TEWL) and stratum corneum hydration were measured on Days 0, 14, and 28. Because baselines were unavailable for the second 2-week period, the primary analysis compared Day 0–14 changes between groups using baseline-adjusted analysis of covariance; Day 0–28 changes were also explored. The primary outcomes were EASI changes; TEWL and hydration were the secondary outcomes. Groups used a conventional shower (control) first and then FB shower second or vice versa (once each). Twenty-three participants were analyzed (mean age 40.9 ± 8 years; 83% male). Day 0–14 EASI changes did not differ between FB and control (0.62 ± 2.21 vs. 0.05 ± 0.68; F = 0.93, p = 0.35). EASI changes to Day 28 were nonsignificant (0.02 ± 1.65 vs. −0.03 ± 1.02; p = 0.90). TEWL changes for Days 0–14 (0.31 ± 4.75 vs. 1.09 ± 6.21 g/m2/h) and to Day 28 (5.49 ± 14.43 vs. −0.27 ± 5.28 g/m2/h) showed no between-group differences. Hydration changes were similar for Days 0–14 (5.53 ± 13.23 vs. 6.14 ± 7.96 AU) and to Day 28 (18.41 ± 10.33 vs. 21.09 ± 11.07 AU). No serious adverse events or discontinuations for worsening symptoms occurred. Under standardized, low-irritant conditions, the FB shower was well-tolerated by adults with mild AD and did not worsen severity or barrier indices over 4 weeks. However, the superiority of FB to a conventional shower was not demonstrated.
KW - atopic dermatitis
KW - crossover studies
KW - double-blind method
KW - fine bubble
KW - microbubbles
KW - randomized clinical trials
UR - https://www.scopus.com/pages/publications/105025010203
UR - https://www.scopus.com/pages/publications/105025010203#tab=citedBy
U2 - 10.1111/1346-8138.70117
DO - 10.1111/1346-8138.70117
M3 - Article
C2 - 41404883
AN - SCOPUS:105025010203
SN - 0385-2407
VL - 53
SP - 447
EP - 453
JO - Journal of Dermatology
JF - Journal of Dermatology
IS - 3
ER -